Related Experiment Video

Updated: Mar 31, 2026

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

1.2K

Infectious Diseases Pharmacotherapy for Children With Cystic Fibrosis

Leah Molloy, Kristen Nichols

    Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners
    |October 27, 2015
    PubMed

    Insights

    Pediatric cystic fibrosis (CF) requires specialized antimicrobial strategies due to unique respiratory infections. This review covers pathogens, drug pharmacology, and dosing for effective CF patient care.

    Area of Science:

    • Pulmonology
    • Infectious Diseases
    • Pediatric Pharmacology

    Background:

    • Cystic Fibrosis (CF) impacts multiple organs, particularly the lungs, increasing susceptibility to severe infections.
    • Physiological changes and infection characteristics in CF necessitate tailored antimicrobial approaches.
    • Standard antimicrobial practices may not be suitable for CF patients, especially children.

    Purpose of the Study:

    • To review common respiratory pathogens in pediatric cystic fibrosis.
    • To discuss the pharmacology of frequently used antimicrobial agents in CF.
    • To outline unique pharmacokinetic and dosing strategies for treating CF in children.

    Main Methods:

    • Literature review of common respiratory pathogens in CF.
    • Analysis of antimicrobial agent pharmacology relevant to CF.
    • Examination of pharmacokinetic data and dosing adjustments for pediatric CF patients.

    Main Results:

    • Identification of key respiratory pathogens in CF.
    • Overview of antimicrobial drug properties and their application in CF.
    • Discussion of specialized dosing regimens and pharmacokinetic considerations.

    Conclusions:

    • Optimizing antimicrobial therapy in pediatric CF requires understanding specific pathogens and drug behaviors.
    • Tailored selection, dosing, and administration of antimicrobials are crucial for effective CF management.
    • Pediatric healthcare providers need awareness of these unique aspects for optimal patient outcomes.

    Keywords:
    CFCystic Fibrosis ID PharmacologyCystic Fibrosis ID Pharmacotherapy

    More Related Videos

    Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

    Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

    Published on: April 19, 2024

    1.3K
    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

    Published on: August 29, 2025

    686

    Related Concept Videos

    Cystic Fibrosis: Management01:24

    Cystic Fibrosis: Management

    Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
    Sinus disease and chronic...
    620
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    374
    Cystic Fibrosis: Pathogenesis01:23

    Cystic Fibrosis: Pathogenesis

    Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
    CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
    1.1K
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    332
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    732
    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    947